Compare ARK Fintech Innovation ETF (ARKF) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Zimmer Biomet Holdings Inc — how do they compare? ARK Fintech Innovation ETF trades at $41.45, while Zimmer Biomet Holdings Inc trades at $91.8 (market cap $17.67B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while ARK Fintech Innovation ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $107.71 |
52-Week Low | $36.14 | $79.58 |
Market Cap | — | $17.67B |
Enterprise Value | — | $24.72B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $41.63, up 0.43% with bullish technical signals from moving averages and strong trend strength (ADX 39.69). The stock faces resistance at $42 with support at $41. Recent coverage highlights institutional interest in Cathie Wood's and Bill Ackman's overlapping investments in Magnificent Seven stocks.
The ETF's outlook is supported by technical momentum but lacks fundamental financial data disclosure. Key risks include market volatility and dependency on top holdings performance. Institutional overlap suggests confidence in selected growth stocks, though valuation metrics remain undisclosed.
Zimmer Biomet (ZBH) trades at $91.34, up 2.36% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong profitability with a 70.03% gross margin and has beaten earnings estimates for three consecutive quarters. Recent developments include a $140M acquisition and plans to hire 500 employees in India, signaling growth initiatives.
Outlook is cautiously optimistic with a consensus price target of $98.00, though rising debt levels and competitive pressures pose risks. The stock offers steady dividend income and share repurchases, but investors should weigh execution risks against solid cash flow generation and market positioning in medical devices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
